Haim Shani Concludes Tenure at Cellebrite as Company Enters Next Growth Phase
March 06 2024 - 7:00AM
Cellebrite DI Ltd. (Nasdaq: CLBT), a leader in premier Digital
Investigative solutions for the public and private sectors, today
announced that Haim Shani has retired as a director of the Company,
effective immediately. Mr. Shani had been a distinguished member of
the Board since 2019, including two years as Chairman from August
2021 until August 2023.
Reflecting on his departure, Mr. Shani remarked, "The pace of
progress at Cellebrite over the past year has been exceptional. As
Cellebrite moves into its next phase of growth and market
leadership, I believe it is the right moment for me to conclude my
board service. I am leaving with pride in the Company’s
accomplishments and confidence that the Company is well positioned
to enjoy further success."
Yossi Carmil, CEO of Cellebrite, expressed his gratitude for Mr.
Shani’s contributions: “Haim has been an integral part of our
journey, providing strategic guidance that has been vital to our
achievements. On behalf of the board and the entire Cellebrite
team, I want to thank him for his dedication and impactful
contributions. We wish him the very best going forward.”
Following Mr. Shani’s departure, Cellebrite’s Board of Directors
shall consist of nine directors.
Cellebrite moves forward as a global leader in Digital
Investigative solutions, dedicated to enabling its customers to
master the complexities of legally sanctioned digital
investigations. The board and leadership team remain focused on
addressing the evolving needs of its expansive global customer base
through ongoing innovation and go-to-market initiatives and
expanding its business around the world.
About Cellebrite
Cellebrite’s mission is to enable its customers to protect and
save lives, accelerate justice, and preserve privacy in communities
around the world. We are a global leader in Digital Investigative
solutions for the public and private sectors, empowering
organizations to master the complexities of legally sanctioned
digital investigations by streamlining intelligence processes.
Trusted by thousands of leading agencies and companies worldwide,
Cellebrite’s Digital Investigative platform and solutions transform
how customers collect, review, analyze, and manage data in legally
sanctioned investigations. To learn more, visit us at
www.cellebrite.com, https://investors.cellebrite.com, or follow us
on Twitter at @Cellebrite.
Caution Regarding Forward Looking
Statements
This document includes “forward-looking statements” within the
meaning of the “safe harbor” provisions of the United States
Private Securities Litigation Reform Act of 1995. Forward looking
statements may be identified by the use of words such as
“forecast,” “intend,” “seek,” “target,” “anticipate,” “will,”
“appear,” “approximate,” “foresee,” “might,” “possible,”
“potential,” “believe,” “could,” “predict,” “should,” “could,”
“continue,” “expect,” “estimate,” “may,” “plan,” “outlook,”
“future” and “project” and other similar expressions that predict,
project or indicate future events or trends or that are not
statements of historical matters. Such forward-looking statements
include, but are not limited to, confidence that Company is well
positioned to enjoy further success. Such forward-looking
statements are based on current expectations that are subject to
risks and uncertainties. A number of factors could cause actual
results or outcomes to differ materially from those indicated by
such forward-looking statements. These factors include, but are not
limited to: Cellebrite’s ability to keep pace with technological
advances and evolving industry standards; Cellebrite’s material
dependence on the purchase, acceptance and use of its solutions by
law enforcement and government agencies; real or perceived errors,
failures, defects or bugs in Cellebrite’s DI solutions;
Cellebrite’s failure to maintain the productivity of sales and
marketing personnel, including relating to hiring, integrating and
retaining personnel; intense competition in all of Cellebrite’s
markets; the inadvertent or deliberate misuse of Cellebrite’s
solutions; failure to manage its growth effectively; Cellebrite’s
ability to introduce new solutions and add-ons; its dependency on
its customers renewing their subscriptions; the low volume of
business Cellebrite conducts via e-commerce; risks associated with
the use of artificial intelligence; the risk of requiring
additional capital to support the growth of its business; risks
associated with higher costs or unavailability of materials used to
create its hardware product components; fluctuations in foreign
currency exchange rates; lengthy sales cycle for some of
Cellebrite’s solutions; near term declines in new or renewed
agreements; risks associated with inability to retain qualified
personnel and senior management; the security of Cellebrite’s
operations and the integrity of its software solutions; risks
associated with the negative publicity related to Cellebrite’s
business and use of its products; risks related to Cellebrite’s
intellectual property; the regulatory constraints to which
Cellebrite is subject; risks associated with Cellebrite’s
operations in Israel, including the ongoing Israel-Hamas war and
the risk of a greater regional conflict; risks associated with
different corporate governance requirements applicable to Israeli
companies and risks associated with being a foreign private issuer
and an emerging growth company; market volatility in the price of
Cellebrite’s shares; changing tax laws and regulations; risks
associated with joint, ventures, partnerships and strategic
initiatives; risks associated with Cellebrite’s significant
international operations; risks associated with Cellebrite’s
failure to comply with anti-corruption, trade compliance,
anti-money-laundering and economic sanctions laws and regulations;
risks relating to the adequacy of Cellebrite’s existing systems,
processes, policies, procedures, internal controls and personnel
for Cellebrite’s current and future operations and reporting needs;
and other factors, risks and uncertainties set forth in the section
titled “Risk Factors” in Cellebrite’s annual report on Form 20-F
filed with the SEC on April 27, 2023 and in other documents filed
by Cellebrite with the U.S. Securities and Exchange Commission
(“SEC”), which are available free of charge at www.sec.gov. You are
cautioned not to place undue reliance upon any forward-looking
statements, which speak only as of the date made, in this
communication or elsewhere. Cellebrite undertakes no obligation to
update its forward-looking statements, whether as a result of new
information, future developments or otherwise, should circumstances
change, except as otherwise required by securities and other
applicable laws.
Contacts:
Investor RelationsAndrew KramerVice President,
Investor Relationsinvestors@cellebrite.com +1 973.206.7760
Media Victor CooperSr. Director of Corporate
Communications + Content
OperationsVictor.cooper@cellebrite.com +1 404 804
5910
Cellebrite Digital Intel... (NASDAQ:CLBT)
Historical Stock Chart
From Apr 2024 to May 2024
Cellebrite Digital Intel... (NASDAQ:CLBT)
Historical Stock Chart
From May 2023 to May 2024